Panelists discuss how emerging, better-tolerated oral therapies for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) could improve patient adherence and simplify treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback